Immunotherapy refers to the practice of using medications to stimulate a patient’s immune system so that it is better able to identify and eliminate cancer cells. Boosting the immune response is often accomplished via immunotherapy by acting on specific proteins involved in the immune system. These medications have side effects that are distinct from those caused by chemotherapy. Some immunotherapy for breast cancer medications, such as monoclonal antibodies, for example, function in more than one manner to control cancer cells. Because they interfere with a specific protein on the cancerous cells, these treatments are sometimes referred to as targeted therapy. Immunotherapy is a kind of treatment that helps with some breast cancers.
Inhibitors Of Immune Checkpoints For The Treatment Of Breast Cancer
The immune system must be able to prevent itself from attacking healthy cells in the body. It is an essential function of the immune system. To do this, it makes use of proteins (also known as “checkpoints”) that are located on immune cells and need to be activated (or deactivated) before an immune response can begin. These checkpoints are occasionally used by breast cancer cells to evade being assaulted by the immune system. The immune response against breast cancer cells may be helped to return to normal with drugs and breast cancer treatment Mexico targeting specific checkpoint proteins.
Pd-1 Inhibitor- Pembrolizumab (Keytruda) For Breast Cancer
Keytruda, also known as pembrolizumab, is an immunotherapy for breast cancer medication that targets PD-1 protein. These medications aim to enhance the immune response against breast cancer cells by inhibiting the PD-1 protein. It has the potential to reduce the size of tumors. In combination with chemotherapy, it may be an effective treatment for triple-negative breast cancer:
- Before and after surgery for malignancies of stage 2 or 3, which have returned locally but cannot be removed surgically because they have migrated to other areas of the body
- This medication is usually administered through intravenous (IV) infusion once every three to six weeks. If your cancer cells test positive for the PD-L1 protein, this indicates that your cancer is more likely to react favorably to treatment with pembrolizumab. However, this only applies in certain circumstances.
Infusion reactions: While receiving these medications for breast cancers treatment Mexico, some individuals could have an adverse response to the infusion. The symptoms of this condition are similar to those of an allergic response. They might include a high temperature, chills, a flushed face, a rash, itchy skin, dizziness, wheezing, and difficulty breathing. You must communicate immediately with your healthcare provider or nurse if you have any of these symptoms while taking these medications.
Autoimmune reactions: This immunotherapy for breast cancer medications removes one of the safeguards the immune system typically provides for the body. Sometimes the immune response will begin attacking different bodily parts, causing serious or even life-threatening issues with the liver, kidneys, intestines, lungs, and other systems. These problems can be caused by the immune system’s mistaken belief that other body parts are infected with a harmful pathogen.
Conclusion
You must notify your healthcare staff immediately of any new negative effects you experience. If you have significant adverse effects, your breast cancer treatment Mexico will stop and be given high doses of corticosteroids to slightly weaken your immune system.
